After increasing sales by 10% in the first six months, Africa's largest drug maker Aspen Pharmacare is pinning its hopes on more contract manufacturing to further raise predictable business growth into the future. Aspen says it has completed trials and validation to produce mRNA drugs at its sterile plant in France. The benefit from this will start flowing into the revenue line in that last quarter of this financial year, said Aspen on Monday.